U.S. Professional Services Stock News

NYSE:TE
NYSE:TEElectrical

Is It Too Late To Consider T1 Energy After Its 171.3% Share Price Surge?

Wondering if T1 Energy is still a bargain after its big run, or if you are turning up just as the value story is fading? This breakdown is built to answer that exact question. The stock has surged 15.3% over the last week and 34.5% over the past month, capping off a huge 171.3% gain over the last year despite a flat YTD performance and weak longer term returns. Recent attention has centered on T1 Energy's push into new project contracts and strategic partnerships, which investors see as...
NasdaqGM:OMER
NasdaqGM:OMERPharmaceuticals

Will FDA Approval of YARTEMLEA in TA-TMA Redefine Omeros' (OMER) Commercial Trajectory?

Omeros Corporation has announced that the FDA previously approved YARTEMLEA (narsoplimab-wuug) for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with U.S. launch preparations and dedicated billing codes now in place. This approval gives Omeros its first marketed complement-inhibiting therapy in a rare, high-need indication, supported by a tailored patient assistance program and a long-acting MASP-2 inhibitor emerging from Phase 1 trials. We will now...